Geographic Atrophy Secondary to Age-related Macular Degeneration

• CLINICAL_TRIALS research · 2026-03-30
  Clinical Trial Update: A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio [Phase 2]

  Phase 2 randomized, placebo-controlled trial evaluating multidose APL-3007 in combination with pegylated complement inhibitor Syfovre (pegce…

• CLINICAL_TRIALS research · 2025-12-09
  Clinical Trial Update: A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration [Phase 1, Phase 2]

  A Phase 1/2 clinical trial evaluating KRIYA-825 (VV-14295) for geographic atrophy due to age-related macular degeneration is currently recru…

• FDA approval · 2025-03-27
  FDA Approved: SYFOVRE — Supplemental Application (Apellis Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for SYFOVRE (pegcetacoplan) from Apellis Pharmaceuticals, Inc. The action signifies an approved …

• FDA approval · 2023-11-30
  FDA Approved: SYFOVRE — Supplemental Application (Apellis Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for SYFOVRE (pegcetacoplan) from Apellis Pharmaceuticals. The snippet does not specify the exact…